Company Filing History:
1 out of 73 
1 out of 1,591 
1 out of 17 
Years Active: 2025
Title: The Innovative Contributions of Eric Yvon
Introduction
Eric Yvon is a notable inventor based in Bethesda, MD, who has made significant strides in the field of cancer research. His work focuses on developing methods and compositions that target cancer cells, particularly those expressing the SSX2 peptide. With one patent to his name, Yvon's contributions are paving the way for advancements in cancer detection and treatment.
Latest Patents
Yvon's patent, titled "Methods and composition for a binding molecule targeting cancer cells expressing SSX2 peptide 41-49 in HLA-A*0201 context," discloses innovative binding molecules and methods for their application in cancer detection and treatment. This patent highlights the potential for improved therapeutic strategies in combating synovial sarcoma and other cancers.
Career Highlights
Throughout his career, Eric Yvon has worked with esteemed institutions such as Children's National Medical Center and Washington University. His experience in these organizations has allowed him to collaborate with leading experts in the field, further enhancing his research and contributions to cancer therapy.
Collaborations
Yvon has collaborated with notable professionals, including Catherine M. Bollard and Stacey Van Pelt. These partnerships have enriched his research endeavors and have played a crucial role in advancing the understanding of cancer treatment methodologies.
Conclusion
Eric Yvon's innovative work in cancer research exemplifies the impact of targeted therapies in modern medicine. His patent and collaborations reflect a commitment to improving patient outcomes in the fight against cancer.